Spelling suggestions: "subject:"breast neoplasias diagnosis.""
1 |
Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early stage and advanced breast cancer.Kandl, H. January 1994 (has links)
A research report submitted to the Faculty of Medicine university of tho
Witwatersrand, Johannesburg, in partial fulfilment of the requirements
for the Degree of Master of science in Medicine. / Breast cancer is a major health problem, afflicting up to 1 in 9 women in developed countries
with Western diet and life style. While screening programs have led to earlier diagnosis,
including diagnosis at a pre-invasive stage in a number of women, the majority of patients with
breast cancer still present with clinically detectable, invasive breast cancer, which even if
clinically localised still carries the risk of systemic micrometastases, Such patients have been
shown to benefit both in terms of disease free as well as of overall survival from the addition
of adjuvant systemic treatment.
The identification of progostic factors which can be used to tailor specific forms of adjuvant
treatment to the patient's disease has been an important goal of breast cancer research during
the last 20 years. A particularly important goal is the early identification of poor risk patients,
who may benefit from aggressive intervention with intensive chemotherapy,
While many prognostic markers, including nodal status, hormone-receptor-status, ploidy and
growth fraction and the expression of various oncogenes and proto-oncogenes by the tumor
cells have been proposed as prognostic factors, the results, to date, have been equivocal for
a number of these. Recently there has been much. interest in the prognostic importance of cerbB-
2 protein in breast cancer. Most of these studies have concentrated on
immunohistochemically stainable e-erb-2 in tumor tissue. This dissertation focusses on the
prognostic impact of the soluble c-erbB-2 protein in the serum of breast cancer patients treated
at the Breast Clinic of tne Johannesburg Hospital and University of the Witwatersrand. The
results of this investigation have been reported under the title "Soluble c-erhB-2 fragment in
Serum Correlates With Disease Stage and Predicts for Shortened Survival in Patients with Early
Stage and Advanced Breast Cancer" by H. Kandt, L. Seymour & W.R. Bezwoda, Published
in British Journal of Cancer, Vo170 p739-742" 1994. / Andrew Chakane 2018
|
2 |
Multiple biochemical markers for breast cancer.January 1998 (has links)
by Yu Xiongwen. / Thesis (M.Sc.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (leaves 74-84). / Abstract also in Chinese. / Acknowledgments --- p.i / Abstract --- p.ii / List of Tables --- p.iii / List of Figures --- p.iv / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Tumor Marker --- p.1 / Chapter 1.1.1 --- General concept of tumor marker --- p.1 / Chapter 1.1.2 --- Application of tumor marker --- p.2 / Chapter 1.1.3 --- Limitation of tumor markers --- p.5 / Chapter 1.2 --- Breast Cancer --- p.6 / Chapter 1.2.1 --- Incidence in Hong Kong Chinese --- p.6 / Chapter 1.2.2 --- Need for early diagnosis and prognosis --- p.8 / Chapter 1.3 --- Markers for Breast Cancer --- p.9 / Chapter 1.3.1 --- Usefulness of tumor marker for breast cancer --- p.9 / Chapter 1.3.2 --- Some tumor marker for breast cancer --- p.12 / Chapter 1.4 --- Selective Markers for Breast Cancer in this Study --- p.16 / Chapter 1.4.1 --- New TPA --- p.16 / Chapter 1.4.2 --- CA 15-3 --- p.19 / Chapter 1.4.3 --- Apolipoprotein(a) --- p.22 / Chapter 1.5 --- Objectives --- p.24 / Chapter Chapter 2 --- Materials and Methods --- p.25 / Chapter 2.1 --- Materials --- p.25 / Chapter 2.1.1 --- Patients and control subjects --- p.25 / Chapter 2.1.2 --- Sampling --- p.25 / Chapter 2.2 --- Methods --- p.26 / Chapter 2.2.1 --- CA 15-3: Cancer Antige 15-3 --- p.26 / Chapter 2.2.2 --- New TP A --- p.27 / Chapter 2.2.3 --- Apolipoprotein(a) --- p.28 / Chapter 2.3 --- Statistical Methods --- p.29 / Chapter Chapter 3 --- Results --- p.32 / Chapter 3.1. --- Precision Studies --- p.32 / Chapter 3.1.1 --- CA 15-3 --- p.32 / Chapter 3.1.2 --- TPA --- p.32 / Chapter 3.1.3 --- Apolipoprotein(a) --- p.32 / Chapter 3.2 --- CA 15-3 --- p.37 / Chapter 3.2.1 --- "CA 15-3 levels in healthy women, patients with benign breast disease and patients with breast cancer" --- p.37 / Chapter 3.2.2 --- "Sensitivity, specificity, and total accuracy of preoperative CA15-3 determination by cutoff value" --- p.42 / Chapter 3.3 --- TPA --- p.45 / Chapter 3.3.1 --- TPA levels in healthy women,patients with benign breast disease and patients with breast cancer --- p.45 / Chapter 3.3.2 --- "Sensitivity, specificity,and total accuracy of preoperative CA 15-3 determination by cutoff value" --- p.50 / Chapter 3.4 --- Apolipoprotein (a) --- p.53 / Chapter 3.4.1 --- Apo(a) levels in healthy women,patients with benign breast disease and patients with breast cancer --- p.53 / Chapter 3.5 --- Combination Test --- p.59 / Chapter 3.6 --- Study in Pairs --- p.64 / Chapter 3.6.1 --- Results of the pairs investigation --- p.64 / Chapter 3.6.2 --- Changes in post-operation compared with the pre- operation levels --- p.64 / Chapter Chapter 4 --- Discussion --- p.69 / Chapter Chapter 5 --- Conclusion --- p.73 / References --- p.74
|
3 |
Caracterização da expressão de microRNAS em carcinoma de mama triplo negativo / Characterization of the expression of microRNAs in triple negative breast carcinomaCalvano Filho, Carlos Marino Cabral 22 July 2014 (has links)
INTRODUÇÃO: Os microRNAs (miRNAs) são uma classe de pequenas moléculas não codificadoras de proteínas que regulam a expressão gênica durante a etapa de tradução. Esta regulação é feita pelo pareamento de bases com o mRNA-alvo (RNA mensageiro), resultando na supressão da tradução ou na clivagem do mRNA. A depender se os miRNAs têm como alvo genes supressores de tumor ou oncogenes, eles podem atuar como supressores tumorais ou oncogenes. A imunoistoquímica triplo negativa, no câncer de mama, é, comumente, utilizada como substituto clínico para identificação dos tumores basaloides, que se caracterizam pela expressão de genes epiteliais basais, sendo associados a menores taxas de sobrevida livre de doença e sobrevida global. O câncer de mama triplo negativo faz com que seja necessária a descoberta de marcadores moleculares que possam servir de alvos terapêuticos ou, pelo menos, que sirvam como marcadores preditivos da resposta aos quimioterápicos. OBJETIVO: avaliar a expressão de microRNAs, por PCR em tempo real, no carcinoma mamário ductal invasivo (CDI) triplo negativo. MÉTODOS: Foram avaliados materiais em parafina de tumor de 31 pacientes com as seguintes características: carcinoma invasivo de mama, receptores de estrogênio e de progesterona negativos e HER 2 negativo, bem como tecido mamário histologicamente normal. Foram utilizados kit para extração de RNA de amostras fixadas e parafinadas - miRNeasy FFPE; kit para síntese de cDNA - miScript II RT; kit miScript SYBR Green PCR e miScript miRNA PCR Arrays para análise de 84 sequências de miRNA de câncer humano. Foram avaliados dados clínicos, como idade, paridade, amamentação, status menopausal; variáveis histológicas, como tamanho do tumor, status linfonodal, invasão linfática; características imunoistoquímicas, como expressão de Ki-67, EFGR e CK 5/6. O seguimento das pacientes buscou verificar a ocorrência e o tempo de aparecimento de recidiva loco regional, metástase à distância e óbito. Para análise estatística foi utilizado o software miScript miRNA PCR Array Data Analysis, que utiliza o método de quantificação relativa DeltaCt. RESULTADOS: A análise comparativa dos 31 casos de CDI triplo negativo com os 18 casos de parênquima mamário normal definiu microRNAs hiperexpressos, sendo eles: miR-96-5p (fold-regulation(FR) = 9,68, p = 0,000008), miR-21-5p (FR = 4,47, p = 0,00), miR-7-5p (FR = 5,8, p = 0,00137) , miR-182-5p (FR= 7,92, p = 0,000001), miR-210-3p (FR = 11,83, p = 0,000048), miR-18a-5p (FR = 9,51, p = 0,000034), miR-155-5p (FR= 4,40 , p = 0,00019) e miR-93-5p (FR= 4,15, p = 0,000023). Aponta, ainda, microRNAs com hipoexpressão, a saber: miR-204-5p (FR = -10,26, p = 0), miR-205-5p (FR= -4,07, p = 0,019822), miR-125b-5p (FR= -4,29, p=0) e let 7c-5p (FR= -4,91, p=0). CONCLUSÃO: a expressão de microRNAs no carcinoma ductal invasivo triplo negativo permite diferenciá-lo do tecido normal / INTRODUCTION: MicroRNAs (miRNAs) are a class of small non-coding protein molecules that regulate gene expression during the translation stage. This adjustment is made by base pairing with the mRNA (messenger RNA) target resulting in suppression of translation or cleavage of the mRNA. Depending on whether miRNAs target tumor suppressor genes or oncogenes, they can act as tumor suppressors or oncogenes. The triple negative immunohistochemistry in breast cancer is commonly used as a substitute for clinical identification of basaloid tumors, which are characterized by the expression of basal epithelial genes and are associated with lower rates of disease-free survival and overall survival. The triple negative breast cancer makes necessary the discovery of molecular markers that may serve as therapeutic targets or at least as predictive markers of response to chemotherapy. OBJECTIVE: evaluate the expression of microRNAs by RT-PCR in triple negative breast invasive ductal carcinoma (IDC). METHODS: Paraffin embedded tumor material from 31 patients with the following characteristics were evaluated: invasive breast carcinoma, negative estrogen and progesterone receptor, negative HER 2, and histologically normal breast tissue. Were used: Kit for RNA extraction from fixed and paraffin embedded samples - miRNeasy FFPE; cDNA synthesis kit - miScript II RT; miScript SYBR Green PCR Kit and miScript miRNA PCR Arrays for analysis of 84 miRNA sequences of human cancer. Clinical data such as age, parity, breastfeeding, menopausal status; histological variables such as tumor size, lymph node status, lymphatic invasion; immunohistochemical characteristics, such as expression of Ki-67, EFGR and CK 5/6 were evaluated. The follow-up of patients aimed to verify the occurrence and time of appearance of loco regional recurrence, distant metastasis and death. For statistical analysis the miScript miRNA PCR Array Data Analysis software, which uses the method of relative quantification DeltaCt, was used. RESULTS: A comparative analysis of 31 cases of triple negative IDC with 18 cases of normal breast parenchyma defined microRNAs overexpressed, as follows: miR-96-5p (fold-regulation (FR) = 9.68, p = 0.000008), miR -21-5p (FR = 4.47, p = 0.00), 5p, miR-7 (FR = 5.8, p = 0.00137), miR-182-5p (FR = 7.92, p = 0.000001), miR-210-3p (FR = 11.83, p = 0.000048), miR-18a-5p (FR = 9.51, p = 0.000034), miR-155-5p (FR = 4.40, p = 0.00019) and miR-93-5p (FR = 4.15, p = 0.000023). Furthermore, microRNAs with reduced expression, as follows: miR-204-5p (FR = -10.26, p = 0), miR-205-5p (FR = -4.07, p = 0.019822), miR -125b-5p (FR = -4.29, p = 0) and Let-7c 5p (FR = -4.91, p = 0). CONCLUSION: the expression of microRNAs in triple negative invasive ductal carcinoma allows to differentiate it from normal tissue
|
4 |
Caracterização da expressão de microRNAS em carcinoma de mama triplo negativo / Characterization of the expression of microRNAs in triple negative breast carcinomaCarlos Marino Cabral Calvano Filho 22 July 2014 (has links)
INTRODUÇÃO: Os microRNAs (miRNAs) são uma classe de pequenas moléculas não codificadoras de proteínas que regulam a expressão gênica durante a etapa de tradução. Esta regulação é feita pelo pareamento de bases com o mRNA-alvo (RNA mensageiro), resultando na supressão da tradução ou na clivagem do mRNA. A depender se os miRNAs têm como alvo genes supressores de tumor ou oncogenes, eles podem atuar como supressores tumorais ou oncogenes. A imunoistoquímica triplo negativa, no câncer de mama, é, comumente, utilizada como substituto clínico para identificação dos tumores basaloides, que se caracterizam pela expressão de genes epiteliais basais, sendo associados a menores taxas de sobrevida livre de doença e sobrevida global. O câncer de mama triplo negativo faz com que seja necessária a descoberta de marcadores moleculares que possam servir de alvos terapêuticos ou, pelo menos, que sirvam como marcadores preditivos da resposta aos quimioterápicos. OBJETIVO: avaliar a expressão de microRNAs, por PCR em tempo real, no carcinoma mamário ductal invasivo (CDI) triplo negativo. MÉTODOS: Foram avaliados materiais em parafina de tumor de 31 pacientes com as seguintes características: carcinoma invasivo de mama, receptores de estrogênio e de progesterona negativos e HER 2 negativo, bem como tecido mamário histologicamente normal. Foram utilizados kit para extração de RNA de amostras fixadas e parafinadas - miRNeasy FFPE; kit para síntese de cDNA - miScript II RT; kit miScript SYBR Green PCR e miScript miRNA PCR Arrays para análise de 84 sequências de miRNA de câncer humano. Foram avaliados dados clínicos, como idade, paridade, amamentação, status menopausal; variáveis histológicas, como tamanho do tumor, status linfonodal, invasão linfática; características imunoistoquímicas, como expressão de Ki-67, EFGR e CK 5/6. O seguimento das pacientes buscou verificar a ocorrência e o tempo de aparecimento de recidiva loco regional, metástase à distância e óbito. Para análise estatística foi utilizado o software miScript miRNA PCR Array Data Analysis, que utiliza o método de quantificação relativa DeltaCt. RESULTADOS: A análise comparativa dos 31 casos de CDI triplo negativo com os 18 casos de parênquima mamário normal definiu microRNAs hiperexpressos, sendo eles: miR-96-5p (fold-regulation(FR) = 9,68, p = 0,000008), miR-21-5p (FR = 4,47, p = 0,00), miR-7-5p (FR = 5,8, p = 0,00137) , miR-182-5p (FR= 7,92, p = 0,000001), miR-210-3p (FR = 11,83, p = 0,000048), miR-18a-5p (FR = 9,51, p = 0,000034), miR-155-5p (FR= 4,40 , p = 0,00019) e miR-93-5p (FR= 4,15, p = 0,000023). Aponta, ainda, microRNAs com hipoexpressão, a saber: miR-204-5p (FR = -10,26, p = 0), miR-205-5p (FR= -4,07, p = 0,019822), miR-125b-5p (FR= -4,29, p=0) e let 7c-5p (FR= -4,91, p=0). CONCLUSÃO: a expressão de microRNAs no carcinoma ductal invasivo triplo negativo permite diferenciá-lo do tecido normal / INTRODUCTION: MicroRNAs (miRNAs) are a class of small non-coding protein molecules that regulate gene expression during the translation stage. This adjustment is made by base pairing with the mRNA (messenger RNA) target resulting in suppression of translation or cleavage of the mRNA. Depending on whether miRNAs target tumor suppressor genes or oncogenes, they can act as tumor suppressors or oncogenes. The triple negative immunohistochemistry in breast cancer is commonly used as a substitute for clinical identification of basaloid tumors, which are characterized by the expression of basal epithelial genes and are associated with lower rates of disease-free survival and overall survival. The triple negative breast cancer makes necessary the discovery of molecular markers that may serve as therapeutic targets or at least as predictive markers of response to chemotherapy. OBJECTIVE: evaluate the expression of microRNAs by RT-PCR in triple negative breast invasive ductal carcinoma (IDC). METHODS: Paraffin embedded tumor material from 31 patients with the following characteristics were evaluated: invasive breast carcinoma, negative estrogen and progesterone receptor, negative HER 2, and histologically normal breast tissue. Were used: Kit for RNA extraction from fixed and paraffin embedded samples - miRNeasy FFPE; cDNA synthesis kit - miScript II RT; miScript SYBR Green PCR Kit and miScript miRNA PCR Arrays for analysis of 84 miRNA sequences of human cancer. Clinical data such as age, parity, breastfeeding, menopausal status; histological variables such as tumor size, lymph node status, lymphatic invasion; immunohistochemical characteristics, such as expression of Ki-67, EFGR and CK 5/6 were evaluated. The follow-up of patients aimed to verify the occurrence and time of appearance of loco regional recurrence, distant metastasis and death. For statistical analysis the miScript miRNA PCR Array Data Analysis software, which uses the method of relative quantification DeltaCt, was used. RESULTS: A comparative analysis of 31 cases of triple negative IDC with 18 cases of normal breast parenchyma defined microRNAs overexpressed, as follows: miR-96-5p (fold-regulation (FR) = 9.68, p = 0.000008), miR -21-5p (FR = 4.47, p = 0.00), 5p, miR-7 (FR = 5.8, p = 0.00137), miR-182-5p (FR = 7.92, p = 0.000001), miR-210-3p (FR = 11.83, p = 0.000048), miR-18a-5p (FR = 9.51, p = 0.000034), miR-155-5p (FR = 4.40, p = 0.00019) and miR-93-5p (FR = 4.15, p = 0.000023). Furthermore, microRNAs with reduced expression, as follows: miR-204-5p (FR = -10.26, p = 0), miR-205-5p (FR = -4.07, p = 0.019822), miR -125b-5p (FR = -4.29, p = 0) and Let-7c 5p (FR = -4.91, p = 0). CONCLUSION: the expression of microRNAs in triple negative invasive ductal carcinoma allows to differentiate it from normal tissue
|
Page generated in 0.1058 seconds